NCT01132417

Brief Summary

Observational: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

September 19, 2009

Completed
8 months until next milestone

First Posted

Study publicly available on registry

May 28, 2010

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

June 23, 2011

Status Verified

June 1, 2011

Enrollment Period

2.8 years

First QC Date

September 19, 2009

Last Update Submit

June 21, 2011

Conditions

Infections, Bacterial

Keywords

Tigecycline, MDRPatient infected with multidrug resistance bacteria

Study Arms (1)

Multidrug resistant (MDR)bacterial strains

Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance

Interventions

In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistanceDRUG

studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.

Multidrug resistant (MDR)bacterial strains

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Definition: For observational studies only, a description of the population from which the groups or cohorts will be selected (e.g., primary care clinic, community sample, residents of a certain town).

You may qualify if:

  • All patients with infection with MDRs infections will be included

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Faisal Univrsity, Departmentof Microbiology and Immunology,, dammam branh

Dammam, Eastern Province, 31451, Saudi Arabia

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Sputum, whole blood, urine, tissue

MeSH Terms

Conditions

Bacterial Infections

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfections

Study Officials

  • Asim E Ltayeb Diab, MD, Ph D

    Assist. Professor and Consultant Microbiologist

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 19, 2009

First Posted

May 28, 2010

Study Start

September 1, 2009

Primary Completion

June 1, 2012

Study Completion

July 1, 2012

Last Updated

June 23, 2011

Record last verified: 2011-06

Locations

SA(1)